Search

A low-dose radiation approach could help more patients avoid side effects of treatment for head and neck cancer.

… Thursday, January 20, 2022 Robert Rosenfeld thought the lump he felt in his neck in late 2018 was just a symptom of a cold that wouldn’t go away. He visited an ear, nose, and throat specialist who saw nothing upon first examination, but Robert knew something was wrong and asked for a CT scan. The specialist

Cell biologist Michael Overholtzer will succeed DNA replication expert Ken Marians.

… Friday, October 19, 2018 Call it a changing of the guard. Come January 1, 2019, the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) — MSK’s PhD-granting institution — will have a new dean. GSK’s Board of Trustees voted yesterday to appoint cell biologist Michael Overholtzer to this

Seven students have successfully defended their dissertations and will receive their PhD degrees at commencement on May 18.

… Tuesday, May 16, 2017 Summary Seven students will receive their doctorate degrees this week from the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences at Memorial Sloan Kettering. This innovative program prepares the next generation of basic laboratory scientists to work in research areas

Learn more about a new radiopharmaceutical treatment for prostate cancer approved by the FDA for more patients.

… Tuesday, May 20, 2025 President Joseph Biden is one of an https://pmc.ncbi.nlm.nih.gov/articles/PMC10159917/ estimated 120,000 men  living with stage 4 https://www.mskcc.org/cancer-care/types/prostate prostate cancer .  Fortunately, there are effective treatments that can slow or stop prostate cancer

Eric Alonzo successfully defended his thesis in September 2011. He completed his dissertation research in the laboratory of Dr. Derek Sant'Angelo in the Immunology Program.

… Saturday, October 15, 2011 About Eric Alonzo’s Dissertation Research Eric completed his dissertation research in the laboratory of Dr. Derek Sant’Angelo in the Immunology Program. Broadly, the Sant’Angelo lab is focused on the factors that control lymphocyte development. Specifically, Dr. Sant’Angelo

Learn how intermittent fasting is being explored by researchers for possible use in cancer treatment and prevention, including breast cancer.

… Friday, October 9, 2020 Summary An MSK expert explains what is known about the weight-loss technique called intermittent fasting as a tool against breast cancer . Intermittent fasting is one of the most talked-about topics among people looking to lose weight and improve their overall health. The basic

The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook.

… Tuesday, August 22, 2023 The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook. This visionary

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.

… Saturday, June 1, 2013 The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma , according to new Memorial Sloan Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of

MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.

… Wednesday, February 22, 2017 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, published in Nature on February 22, uncover facets

On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.

… Thursday, December 18, 2025 On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators,